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Introduction
The majority of patients with myelodysplastic syndrome
(MDS) present with anemia, and most of them become trans-
fusion dependent during the clinical course of the disease.1,2
Transfusion iron overload is, therefore, a common complica-
tion in MDS, although its impact on clinical outcome varies
considerably in different MDS subtypes.3
The redistribution of transfusion iron from reticuloendothe-
lial to parenchymal cells is modulated by hepcidin, a peptide
that interacts with ferroportin inhibiting the release of iron
from macrophages.4 Hepcidin production is enhanced by iron
and inflammation, suppressed by anemia and hypoxia, and
negatively modulated by the erythroid marrow activity. In
mouse models of beta thalassemia, ineffective erythropoiesis is
typically associated with downregulation of hepcidin, upregu-
lation of ferroportin in the duodenum, and increased iron
absorption.5 Interestingly, increased levels of growth differenti-
ation factor 15 (GDF15) have been found in thalassemia, and
GDF15 has been shown to inhibit hepcidin production in pri-
mary human hepatocytes.6 Although the role of GDF15 as neg-
ative erythropoietic regulator of hepcidin is still debated, these
observations suggest a potential link between ineffective ery-
thropoiesis, release of bone morphogenetic proteins like
GDF15, suppression of hepcidin production, and parenchymal
iron loading in the so-called iron loading anemias. 
Various pathogenetic mechanisms are responsible for ane-
mia in MDS patients.7 Ineffective erythropoiesis is mainly
found in patients with low-risk disease, typically in refractory
anemia with ring sideroblasts,8 whereas reduced proliferation
of the erythroid marrow is observed in those with advanced
disease and excess of blasts.7 Recently, we identified somatical-
ly acquired mutations in SF3B1, a gene encoding a core com-
ponent of the RNA splicing machinery, in MDS patients with
ring sideroblasts.9,10 This genotype-phenotype correlation was
also shown in subjects having a proportion of ring sideroblasts
below the diagnostic threshold of 15%.10 These observations
strongly support a causal relationship between SF3B1 muta-
tions and ring sideroblasts,9 and suggest a link between SF3B1
mutations and both ineffective erythropoiesis and parenchy-
mal iron loading.8,10 To investigate this link, we studied the rela-
tionship between SF3B1 mutation status, erythroid marrow
activity, hepcidin level, and body iron status in a cohort of
MDS patients. 
Design and Methods
These investigations were approved by the Ethics Committee of the
“Fondazione Istituto di Ricovero e Cura a Carattere Scientifico”
(IRCCS) Policlinico San Matteo, Pavia, Northern Italy. The procedures
followed were in accordance with the Helsinki Declaration of 1975, as
revised in 2000, and samples were obtained after subjects provided
informed consent.
We studied 76 patients with MDS or myelodysplastic/myeloprolif-
erative neoplasm (MDS/MPN) followed at the Department of
Hematology, “Fondazione IRCCS Policlinico San Matteo”, Pavia,
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Somatic mutations of the RNA splicing machinery have been recently identified in myelodysplastic syndromes.
In particular, a strong association has been found between SF3B1mutation and refractory anemia with ring sider-
oblasts, a condition characterized by ineffective erythropoiesis and parenchymal iron overload. We studied the
relationship between SF3B1 mutation, erythroid activity and hepcidin levels in myelodysplastic syndrome
patients. Erythroid activity was evaluated through the proportion of marrow erythroblasts, soluble transferrin
receptor and serum growth differentiation factor 15. Significant relationships were found between SF3B1 muta-
tion and marrow erythroblasts (P=0.001), soluble transferrin receptor (P=0.003) and serum growth differentiation
factor 15 (P=0.033). Serum hepcidin varied considerably, and multivariable analysis showed that the hepcidin to
ferritin ratio, a measure of adequacy of hepcidin levels relative to body iron stores, was inversely related to the
SF3B1 mutation (P=0.013). These observations suggest that patients with SF3B1 mutation have inappropriately
low hepcidin levels, which may explain their propensity to parenchymal iron loading. 
ABSTRACT
northern Italy. This cohort belongs to the patient population of our
recent study on clinical significance of SF3B1 mutations.10
According to the 2001 and 2008 World Health Organization
(WHO) classification criteria,11,12 26 patients had refractory anemia
with ring sideroblasts (RARS) or refractory cytopenia with multi-
lineage dysplasia (RCMD) and ring sideroblasts (RCMD-RS), 22
patients had refractory anemia (RA) with unilineage dysplasia or
RCMD, 23 patients had refractory anemia with excess blasts
(RAEB) type 1 (RAEB-1) or RAEB type 2 (RAEB-2), and 5 patients
had RARS associated with marked thrombocytosis (RARS-T).
Clinical and hematologic features of the patient cohort are report-
ed in Table 1. Risk assessment was based on the WHO-based prog-
nostic scoring system (WPSS)13 accounting for severity of anemia.3
Soluble transferrin receptor (sTfR), a measure of total erythroid
activity,14 was quantified using an immunonephelometric method
(Dade Behring Marburg GmbH, Marburg, Germany) on a BN II
System analyzer. Serum erythropoietin (Epo) was assayed by a
solid-phase chemiluminescent immunometric method (Immulite
2000 Analyzer, Siemens Medical Solution Diagnostics, Los
Angeles, CA, USA). The quantification of serum GDF15 was per-
formed with DuoSet ELISA for human GDF15 (R&D Systems,
Abingdon, UK). Serum ferritin was assayed using a nephelometric
method (N Latex Ferritin, Siemens Healthcare Diagnostic Products,
Marburg, Germany) on a BN II System analyzer.
Serum hepcidin-25 measurements were performed by a combi-
nation of weak cation exchange chromatography and time-of-
flight mass spectrometry (WCX-TOF MS).15 Peptide spectra were
generated on a Microflex LT matrix-enhanced laser desorption/ion-
ization TOF MS platform (Bruker Daltonics). Serum hepcidin-25
concentrations were expressed as nmol/L (nM). The lower limit of
detection of this method was 0.5 nM; average coefficients of vari-
ation were 2.7% (intra-run) and 6.5% (inter-run). The reference
range of serum hepcidin-25 is from less than 0.5 to 14.7 nM (medi-
an 4.5 nM) for men, from less than 0.5 to 12.3 nM (median 2.0 nM)
for premenopausal women, and from less than 0.5 to 15.6 nM
(median 4.9 nM) for postmenopausal women.
Mononuclear cells were separated from peripheral blood or
bone marrow samples by standard density gradient centrifugation.
Granulocyte and T-lymphocytes were isolated from peripheral
blood as previously described.16 Genomic DNA was extracted
from granulocytes, T lymphocytes, or mononuclear bone marrow
cells by following standard protocols for human tissue.
The coding exons of SF3B1 were screened using massively par-
allel pyrosequencing of DNA pools using the genome sequencer
FLX 454 system (Roche, Branford, CT, USA) as previously
described in detail.10
Numerical variables are summarized by median and range; cat-
egorical variables are described with count and relative frequency
(%) of subjects in each category. Comparison of numerical vari-
ables between groups was carried out using a non-parametric
approach (Mann-Whitney test or Kruskall Wallis ANOVA).
Correlations between quantitative variables were assessed using
Spearman’s rank correlation. Independent predictors of variables
of interest were assessed using multivariable generalized linear
regression models. Statistical analyses were performed using Stata
11.2 software (StataCorp LP, College Station, TX, USA).
Results and Discussion
Somatic mutations of SF3B1 were found in 21 of 76
(28%) patients. The proportion of positive patients was sig-
nificantly higher in WHO categories defined by ring sider-
oblasts (17 of 31 or 55%) than in other categories (4 of 45 or
9%) (P<0.001). The median value for SF3B1 mutant allele
burden was 45% (range 7%-64%).
The relationship between SF3B1 mutant allele burden
and erythroid activity is illustrated in Figure 1, while addi-
tional information is provided in the Online Supplementary
Appendix. There was a significant relationship between
SF3B1 mutation and sTfR level (P=0.003), and between
SF3B1 mutant allele burden and sTfR (r=0.38, P=0.001). A
significant association between SF3B1 mutation and
GDF15 levels was observed, patients carrying a SF3B1
mutation having higher values than those without muta-
tion (P=0.033). In addition, a positive correlation was found
between SF3B1 mutant allele burden and GDF15 (r=0.28,
P=0.016). 
Variable hepcidin levels were found in the patients stud-
ied (median value 7.1 nM, range from less than 0.5 to 92.0
nM). There was a significant relationship between hepcidin
and serum ferritin (r=0.59, P<0.001). A significant interac-
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Table 1. Demographic, clinical and hematologic features of the study
population.
N. of patients                                                              76
Male/female                                                                              40 (53%)/ 36 (47%)
Age (years)                                                                               67 (29-83)
WHO subgroups*
RA/RCMD                                                                                  22 (29%)
RARS/RCMD-RS                                                                       26 (34%)
RAEB-1/RAEB-2                                                                       23 (30%)
RARS-T                                                                                      5 (7%)
WPSS risk group†
Very low                                                                                    11 (15%)
Low                                                                                            26 (37%)
Intermediate                                                                           12 (17%)
High                                                                                            18 (25%)
Very high                                                                                   4 (6%)
Karyotype
Normal                                                                                      34 (45%)
Abnormal                                                                                  38 (50%)
Not available                                                                            4 (5%)
Transfusion dependency                                                      25 (33%)
Complete blood count
Hemoglobin (g/dL), median (range)                                9.4 (6.1-13.7)
Absolute neutrophil count (x109/L),                                  2.2 (1.9-12.6)
median (range)
Platelet count (x109/L), median (range)                          134 (17-797)
Bone marrow features
Bone marrow blasts (%), median (range)                      3 (0-19)
Bone marrow erythroblasts (%), median (range)        26 (8-79)
Bone marrow ring sideroblasts(%), median (range)   8 (0-94)
Dyserythropoiesis:
Mild                                                                                     15 (20%)
Moderate                                                                           38 (50%)
Severe                                                                                23 (30%)
Serum iron (g/dL), median (range)                                  167 (61-346)
Transferrin (mg/dL), median (range)                                184 (94-329)
Transferrin saturation (%), median (range)                    53 (20-100)
Serum ferritin (ng/mL), median (range)                          409 (6-8340)
WHO: World Health Organization; RA: refractory anemia; RCMD: refractory cytopenia
with multilineage dysplasia; RARS: refractory anemia with ring sideroblasts; RCMD-RS:
refractory cytopenia with multilineage dysplasia and ring sideroblasts; RAEB-1: refracto-
ry anemia with excess blasts type 1; RAEB-2: refractory anemia with excess blasts type
2; RARS-T: refractory anemia with ring sideroblasts associated with marked thrombocy-
tosis. WPSS: WHO classification-based Prognostic Scoring System. WPSS risk was not
estimated in the 5 RARS-T patients.
tion between SF3B1 mutation and serum ferritin was
observed in a multivariable linear regression model on
serum hepcidin level (P=0.005), suggesting a blunted hep-
cidin response to iron overload in SF3B1-mutated patients
(reflected in the lower slope of the gray regression line in
Figure 2).
We then calculated the hepcidin to ferritin ratio, which
represents a measure of adequacy of hepcidin levels relative
to body iron stores. Significantly lower values of hepcidin
to ferritin ratio were found in patients with SF3B1mutation
compared with those without mutation (P=0.004), and a
significant relationship was observed between hepcidin to
ferritin ratio and SF3B1 mutant allele burden (r=-0.37,
P=0.001) (Figure 1). The relationship between hepcidin to
ferritin ratio and measurements of erythroid activity is illus-
trated in Online Supplementary Figure S1.
Multivariable analyses were performed in order to identi-
fy the most important factors affecting hepcidin level and
hepcidin to ferritin ratio in MDS patients (Online
Supplementary Table S1). In a multivariable analysis includ-
ing hemoglobin, Epo, sTfR, GDF15, bone marrow blasts,
cytogenetic risk groups and SF3B1mutant allele burden, the
hepcidin to ferritin ratio was independently associated with
SF3B1mutant allele burden (P=0.013).
The above findings indicate that MDS patients carrying a
somatic mutation of SF3B1 not only have a distinct clinical
phenotype characterized by ring sideroblasts,9,10 but show
also evidence of ineffective erythropoiesis and relative hep-
cidin deficiency, i.e. typical features of iron loading anemias.
In particular, patients with SF3B1 mutation had high pro-
portions of bone marrow erythroblasts and high levels of
sTfR, both measures of total erythroid activity, and slightly
increased levels of GDF15, a measure of ineffective erythro-
poiesis.6,17-19
The SF3B1mutant allele burden was independently asso-
ciated with hepcidin levels and the hepcidin to ferritin ratio.
This suggests that expanded but ineffective erythropoiesis
may suppress hepcidin production in MDS patients carry-
ing a mutation of SF3B1, and lead to hepcidin levels that are
inappropriately low relative to body iron stores.20
Consistent with this observation, in a previous study on
hepcidin levels in MDS,21 WHO category remained a signif-
icant predictor of hepcidin in multivariate analyses adjusted
for ferritin and transfusion history, and the lowest levels
were indeed found in RARS patients.
It should be noted, however, that in our study the SF3B1
mutation retained an effect on hepcidin level independently
of erythroid marrow activity, suggesting that the mutant
I. Ambaglio et al.
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Figure 1. Relationship between
SF3B1 mutant allele burden and
measurements of erythroid mar-
row activity or hepcidin to ferritin
ratio in MDS patients. (A)
Relationship between SF3B1
mutant allele burden and bone
marrow erythroblasts (r=0.46,
P<0.001). (B) Relationship
between SF3B1 mutant allele
burden and soluble transferrin
receptor level, a measure of total
erythroid activity (r=0.38,
P=0.001). (C) Relationship
between SF3B1 mutant allele
burden and serum GDF15 con-
centration (expressed as ng/mL),
a measure of ineffective erythro-
poiesis (r=0.28, P=0.016). (D)
Relationship between hepcidin to
ferritin ratio and SF3B1 mutant
allele burden. SF3B1 mutant
allele burden was categorized
into groups of comparable size (0,
1-40%, and >40%). Data are
shown in a box plot depicting the
upper and lower adjacent values
(lowest and highest horizontal
line, respectively), lower and
upper quartile with median value
(box), and outside values (dots). 
Figure 2. Linear dependence between hepcidin and serum ferritin
according to SF3B1 mutation status in patients with MDS. Dots and
regression lines of hepcidin and serum ferritin are drawn in black
and gray for patients without and with SF3B1mutation, respectively.
The significant interaction (P=0.005) between SF3B1 mutation and
serum ferritin obtained in a multivariable linear model for serum
hepcidin level is reflected in the lower slope of the gray regression
line, indicating a blunted hepcidin response to iron overload in
SF3B1-mutated patients.
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splicing factor may contribute to hepcidin suppression
through mechanisms other than ineffective erythropoiesis.
Recent studies showed that SF3B1 mutation is associated
with downregulation of essential mitochondrial gene net-
works9 and more specifically of ABCB7,22 and that SF3B1
haploinsufficiency leads to formation of ring sideroblasts.23
It has been previously shown that iron sequestration into
mitochondria results in cytosolic iron depletion and
increased cellular iron uptake.24,25 Therefore, the possibility
exists that abnormal mitochondrial iron homeostasis has an
effect on hepcidin production. 
In conclusion, our study suggests that MDS patients car-
rying a somatic mutation of SF3B1 have inappropriately
low hepcidin levels which may cause excessive reticuloen-
dothelial iron release and parenchymal iron loading. This
may be relevant for decision-making concerning treatment
of transfusion iron overload in MDS patients.26 Taking into
account life expectancy,2,13 clinical consequences of transfu-
sion iron overload,3 and adequacy of hepcidin production,
transfusion-dependent patients with refractory anemia
with ring sideroblasts appear to be those more likely to
develop deleterious consequences of parenchymal iron
overload. These patients may, therefore, benefit from iron
chelation therapy, a very controversial issue in the MDS
community. Despite considerable skepticism, recent studies
have shown improvements in hematologic and hepatic
parameters in MDS patients receiving iron chelation.27,28
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